SCAI Position Statement on Renal Denervation for Hypertension: Patient Selection, Operator Competence, Training and Techniques, and Organizational Recommendations
Rajesh V. Swaminathan, Cara East, Dmitriy N. Feldman, Naomi D.L. Fisher, Joseph Garasic, Jay Giri, David E. Kandzari, Ajay J. Kirtane, Andrew Klein, Taisei Kobayashi, Gerald Koenig, Jun Li, Eric A. Secemsky, Raymond R. Townsend, Herbert D. Aronow
Abstract
Renal Denervation for Treatment of Hypertension: From High-Level Quality Evidence to Implementation in Clinical PracticeJournal of the Society for Cardiovascular Angiography & InterventionsVol. 2Issue 6101130PreviewAccording to the National Health and Nutrition Examination Survey, the rate of blood pressure control (<140/90 mm Hg) of adults in the United States has consistently declined over the past decade (2009-2012: 52.8%, 2013-2016: 51.3%, 2017-2020: 48.2%; P = .034).1 This unsatisfactorily high prevalence of uncontrolled hypertension paradoxically occurs despite the availability of safe, effective, and largely affordable antihypertensive drugs and lifestyle modifications. Thanks to clinical trials investigating device-based therapies for hypertension, which included objective assessment of medication adherence using highly accurate adherence testing of urine and/or plasma, nonadherence to medication has been identified as a major reason for uncontrolled hypertension. Full-Text PDF Open Access